1995
DOI: 10.1016/0029-7844(94)00431-c
|View full text |Cite
|
Sign up to set email alerts
|

Use of a long-acting GnRH agonist for benign cystic mesothelioma

Abstract: Long-acting GnRH agonists may have a role in the conservative management of these rare neoplasms. The reduction in volume concomitant with a hypoestrogenic state and regrowth with addition of add-back therapy further suggest extreme sensitivity of this tumor to one or both hormones.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

1
24
0

Year Published

1998
1998
2020
2020

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 48 publications
(27 citation statements)
references
References 6 publications
1
24
0
Order By: Relevance
“…4 Conservative treatment includes longterm follow-up with or without the use of oral contraceptives to suppress ovulation, thus decreasing the formation of ovarian fluid trapped by adhesions. Gonadotropin-releasing hormone agonist therapy is another medical treatment recently proposed that can be integrated with sonographic follow-up, [23][24][25] used with the same rationale as with contraceptive pills. When the cyst is symptomatic, to reduce the risk of recurrence after open surgery, less invasive treatment than open surgery, such as sonographically guided fine-needle aspiration with or with-out ethanol instillation, followed or not by gonadotropin-releasing hormone agonist therapy, has been successfully proposed, also combined with sonographic diagnosis.…”
Section: Guerriero Et Almentioning
confidence: 99%
“…4 Conservative treatment includes longterm follow-up with or without the use of oral contraceptives to suppress ovulation, thus decreasing the formation of ovarian fluid trapped by adhesions. Gonadotropin-releasing hormone agonist therapy is another medical treatment recently proposed that can be integrated with sonographic follow-up, [23][24][25] used with the same rationale as with contraceptive pills. When the cyst is symptomatic, to reduce the risk of recurrence after open surgery, less invasive treatment than open surgery, such as sonographically guided fine-needle aspiration with or with-out ethanol instillation, followed or not by gonadotropin-releasing hormone agonist therapy, has been successfully proposed, also combined with sonographic diagnosis.…”
Section: Guerriero Et Almentioning
confidence: 99%
“…15 The latter could be useful, particularly when a transformation into a malignant and potentially lethal lesion has been demonstrated. The use of leuprolide or tamoxifen have been suggested when BMPM expresses estrogen and progesterone receptors, 16,17 but as mentioned previously, the role of steroid receptor signaling in these tumors is still unknown. Rosen and Sutton 22 have proposed laparoscopic laser ablation with potassium titanyl phosphate as a potential treatment for the disease.…”
Section: Discussionmentioning
confidence: 95%
“…The use of the gonadotropin-releasing hormone agonist leuprolide and the antiestrogen agent tamoxifen has been reported to reduce cyst size, with a consequent relief in the distension-related symptoms. 16,17 Although Higuchi et al 18 demonstrated the presence of the mRNA for the estrogen, progesterone, and androgen receptors in samples of normal human pelvic peritoneum, the estrogen and progesterone receptor status has not yet been completely investigated. The true biological value of hormonal therapy for these tumors still remains unknown.…”
Section: Discussionmentioning
confidence: 98%
“…1 Transvaginal ultrasound demonstrated a multiloculated cyst size 61·40·55 mm 3 beside the normal left ovary sion cysts. These therapies include the use of tamoxifen [9], and a long-acting GnRH agonist [10]. The role of medical treatment in cases of symptomatic recurrent multiloculated peritoneal inclusion cysts is yet to be determined.…”
Section: Discussionmentioning
confidence: 99%
“…Sometimes this requires removal of attached organs such as ovaries, uterus or spleen [2]. Recurrences of multiloculated peritoneal inclusion cysts after resection have been well documented [3,[8][9][10]. Recently, new medical therapies have been made available for the treatment of recurrent multiloculated peritoneal inclu- Fig.…”
Section: Discussionmentioning
confidence: 99%